Novo Nordisk, one of the leading global players in diabetes care market, will invest 500 million Danish krone (about $ 75 million) in a new 19,000 m2 warehouse in Hillerod, Denmark for handling all inbound raw materials for Novo Nordisk's production in Denmark. The warehouse, which will have a capacity of around 17,000 pallets, is expected to be fully operational end 2017.
“The investment in Hillerod underpins our long-term plans to invest in Denmark. Hillerod is a strategic site in Novo Nordisk and we are consolidating our inbound flow of materials at this site,” said Susanne Hundsbæk-Pedersen, senior vice president of devices & supply chain management, Novo Nordisk.
Established in 1992, the Hillerod site has a total area of about 1,650,000 m2 of which about 90,000 m2 is used for production and R&D facilities. The site encompasses a facility for device R&D and three production facilities for moulding & pre-assembly of components; filling, assembly & packaging of diabetes finished products; and haemophilia API.
“The investment in Hillerod underpins our long-term plans to invest in Denmark. Hillerod is a strategic site in Novo Nordisk and we are consolidating our inbound flow of materials at this site,” said Susanne Hundsbæk-Pedersen, senior vice president of devices & supply chain management, Novo Nordisk.
Established in 1992, the Hillerod site has a total area of about 1,650,000 m2 of which about 90,000 m2 is used for production and R&D facilities. The site encompasses a facility for device R&D and three production facilities for moulding & pre-assembly of components; filling, assembly & packaging of diabetes finished products; and haemophilia API.